Reimbursement & Directory Validation Update

Reimbursement Change
Effective Oct. 1, BCBSWY will begin using J-code level pricing for J-1745 (infliximab). We will no longer be pricing this medication at the NDC code level. Reimbursement will be at the biosimilar rate.

Directory Validation Tip
In Availity, beneath the user account, please select “Manage My Organization” to make updates. (See screenshot below.) Additional instructions are located here to help you find NPI and tax ID combinations. This helps facilitate compliance with the No Surprises Act (NSA) provider directory validation requirements. The NSA requires you confirm this information with us every 90 days, so your information can continue to be listed in our public directory.

Share

Related Posts
Redirection of Care Update – addition of Saphnelo
Effective May 1, 2025, Blue Cross Blue Shield of Wyoming (BCBSWY) will add the following medication to the Redirection of Care program. Saphnelo (HCPCS…
SURGICAL REIMBURSEMENT UPDATE
Updated Rates for Health Care Professionals  Effective July 1, 2025, Blue Cross Blue Shield of Wyoming (BCBSWY) will implement new rates for all surgery…
Evaluation & Managment Reimbursement Update
Effective June 1, 2025, BCBSWY is implementing an increase in reimbursement in the areas of Evaluation and Management (E&M). For questions regarding these changes…

Fewer Hassles. Better Service.

ACA – Online Event Registration Form

Please enable JavaScript in your browser to complete this form.
Name
Email
How did you hear about this event?

Medicare - Event Registration
Medicare - Online Event Registration Form
Please enable JavaScript in your browser to complete this form.
Name
Email
How did you hear about this event?